{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:19:43Z","timestamp":1794575983466,"version":"4.9.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.annonc.2023.10.117","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T10:37:10Z","timestamp":1698057430000},"page":"77-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":448,"title":["Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7575-3870","authenticated-orcid":false,"given":"A.","family":"Passaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Melosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2854-5067","authenticated-orcid":false,"given":"J.-Y.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Juan-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Cortot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Califano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cappuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2087-4963","authenticated-orcid":false,"given":"S.","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-L.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tomasini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8983-6677","authenticated-orcid":false,"given":"R.D.","family":"Gentzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5008-8854","authenticated-orcid":false,"suffix":"Jr.","given":"W.N.","family":"William","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9213-0325","authenticated-orcid":false,"given":"K.L.","family":"Reckamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8407-6763","authenticated-orcid":false,"given":"S.","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1020-2338","authenticated-orcid":false,"given":"A.","family":"Bearz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"MacKean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Barala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9838-0544","authenticated-orcid":false,"given":"A.B.","family":"Bourla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Girvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Greger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Millington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Withelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Diorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.E.","family":"Knoblauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Bauml","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.G.","family":"Campelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.C.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2023.10.117_bib1","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/onc.2009.198","article-title":"Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors","volume":"28","author":"Gazdar","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.annonc.2023.10.117_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","article-title":"Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"4","author":"Vyse","year":"2019","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.annonc.2023.10.117_bib3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.annonc.2023.10.117_bib4","series-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","year":"2020"},{"key":"10.1016\/j.annonc.2023.10.117_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2023.10.117_bib6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2023.10.117_bib7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.annonc.2023.10.117_bib8","doi-asserted-by":"crossref","first-page":"9074","DOI":"10.1200\/JCO.2023.41.16_suppl.9074","article-title":"Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib","volume":"41","author":"Yu","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.10.117_bib9","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","article-title":"Tumor analyses reveal squamous transformation and off-target\u00a0alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2023.10.117_bib10","doi-asserted-by":"crossref","first-page":"9108","DOI":"10.1200\/JCO.2023.41.16_suppl.9108","article-title":"Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: a multi-institutional cohort","volume":"41","author":"Piotrowska","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.10.117_bib11","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2023.10.117_bib12","doi-asserted-by":"crossref","first-page":"viii741","DOI":"10.1093\/annonc\/mdy424.064","article-title":"Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study","volume":"29","author":"Papadimitrakopoulou","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2023.10.117_bib13","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.annonc.2022.02.003","article-title":"ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer","volume":"33","author":"Passaro","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2023.10.117_bib14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2023.10.117_bib15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2023.10.117_bib16","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S1470-2045(15)00121-7","article-title":"Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2023.10.117_bib17","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.annonc.2022.10.350","article-title":"LBA8 - Nivolumab (NIVO)\u00a0+ chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722","volume":"33","author":"Mok","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2023.10.117_bib18","doi-asserted-by":"crossref","first-page":"LBA9000","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9000","article-title":"Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: phase 3 KEYNOTE-789 study","volume":"41","author":"Yang","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.10.117_bib19","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/0008-5472.CAN-15-2833","article-title":"A\u00a0novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors","volume":"76","author":"Moores","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2023.10.117_bib20","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1535-7163.MCT-20-0071","article-title":"Amivantamab (JNJ-61186372), an Fc enhanced EGFR\/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte\/macrophage trogocytosis","volume":"19","author":"Vijayaraghavan","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.annonc.2023.10.117_bib21","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1158\/2159-8290.CD-20-0116","article-title":"Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR exon 20 insertion-driven NSCLC","volume":"10","author":"Yun","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2023.10.117_bib22","series-title":"RYBREVANT. RYBREVANT (amivantamab-vmjw) Injection, for Intravenous Use [prescribing information]","year":"2021"},{"key":"10.1016\/j.annonc.2023.10.117_bib23","author":"Bauml","year":"2021"},{"key":"10.1016\/j.annonc.2023.10.117_bib24","doi-asserted-by":"crossref","first-page":"9009","DOI":"10.1200\/JCO.2019.37.15_suppl.9009","article-title":"JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC)","volume":"37","author":"Haura","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.10.117_bib25","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1200\/JCO.2022.40.16_suppl.9008","article-title":"Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: updated results from the CHRYSALIS study","volume":"40","author":"Krebs","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.10.117_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-023-02554-7","article-title":"Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial","author":"Cho","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2023.10.117_bib27","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1158\/1078-0432.CCR-18-2906","article-title":"YH25448, an irreversible EGFR-TKI with potent intracranial activity in EGFR mutant non\u2013small cell lung cancer","volume":"25","author":"Yun","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2023.10.117_bib28","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S1470-2045(19)30504-2","article-title":"Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study","volume":"20","author":"Ahn","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2023.10.117_bib29","series-title":"Amivantamab and lazertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC) after progression on osimertinib and platinum-based chemotherapy: updated results from CHRYSALIS-2","author":"Shu","year":"2022"},{"key":"10.1016\/j.annonc.2023.10.117_bib30","doi-asserted-by":"crossref","first-page":"S951","DOI":"10.1016\/j.annonc.2021.08.1797","article-title":"1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: analysis from the CHRYSALIS study","volume":"32","author":"Leighl","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2023.10.117_bib31","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1200\/JCO.2023.41.16_suppl.9013","article-title":"Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: analysis of tissue IHC and ctDNA NGS","volume":"41","author":"Besse","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.10.117_bib32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cllc.2021.01.010","article-title":"Combining osimertinib with chemotherapy in EGFR-mutant NSCLC at progression","volume":"22","author":"White","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.annonc.2023.10.117_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2021.08.532","article-title":"P50.04 Amivantamab in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)","author":"Nagasaka","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2023.10.117_bib34","series-title":"Amivantamab and lazertinib in combination with platinum-based chemotherapy in relapsed\/refractory EGFR-mutant NSCLC. Oral presented at the World Conference on Lung Cancer 2022","author":"Marmarelis","year":"2022"},{"key":"10.1016\/j.annonc.2023.10.117_bib35","doi-asserted-by":"crossref","unstructured":"Girard N, Cho BC, Spira AI, et al. Risk factors for venous thromboembolism (VTE) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone. Paper presented at the American Society of Oncology (ASCO) annual meeting; June 2-6, 2023; Chicago, IL, USA.","DOI":"10.1200\/JCO.2023.41.16_suppl.9137"},{"key":"10.1016\/j.annonc.2023.10.117_bib36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2023.10.117_bib37","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1200\/JCO.23.00154","article-title":"Continuation of third-generation tyrosine kinase inhibitors in second-line trials for EGFR-mutated non-small-cell lung cancer: regulatory considerations","volume":"41","author":"Goulart","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.10.117_bib38","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.1016\/j.jtho.2022.07.685","article-title":"EP08.02-003 Aumolertinib plus chemotherapy as 1st line treatment in advanced lung cancer EGFR mutation and ctDNA cleared analysis","volume":"17","author":"Li","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2023.10.117_bib39","doi-asserted-by":"crossref","first-page":"9097","DOI":"10.1200\/JCO.2022.40.16_suppl.9097","article-title":"A\u00a0phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non\u2013small cell lung cancer: the OPAL study (NEJ032C\/LOGIK1801)","volume":"40","author":"Nakamura","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.10.117_bib40","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2021.02.019","article-title":"Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: an open-label, randomised phase 2 clinical trial","volume":"149","author":"Tanaka","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2023.10.117_bib41","first-page":"9","article-title":"Amivantamab, lazertinib plus platinum-based chemotherapy in EGFR-mutated advanced NSCLC: updated results from CHRYSALIS-2. Paper presented at the 2023 World Conference on Lung Cancer (WCLC)","author":"Lee","year":"2023","journal-title":"September"},{"key":"10.1016\/j.annonc.2023.10.117_bib42","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/thoraxjnl-2012-202592","article-title":"Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants: a systematic review and meta-analysis","volume":"68","author":"Zhang","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.annonc.2023.10.117_bib43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000499895","article-title":"A\u00a0retrospective study on efficacy and safety of rivaroxaban and dalteparin for long-term treatment of venous thromboembolism in patients with lung cancer","volume":"98","author":"Lee","year":"2019","journal-title":"Respiration"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423042813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423042813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:13:00Z","timestamp":1762319580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753423042813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0923753423042813"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2023.10.117","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742829902.793601610","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.742829902.793601586","asserted-by":"object"}]},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2023.10.117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}